With cardiovascular conditions leading to critical health complications such as strokes and coronary artery diseases, the focus on creating more effective treatments is paramount. The development of the new 4D-printed vascular stent responds to this urgency. Rather than relying on external heating mechanisms to activate its deployment, this stent automatically expands at physiological temperatures, which could ultimately lead to reduced complication rates and faster recovery times for patients.

The research team, driven by Professor Shinjiro Umezu from Waseda University, consists of an interdisciplinary group of experts from various prestigious institutions across both Japan and China. The collaboration showcases a comprehensive approach, integrating skills from mechanical engineering to biomedical science, all aimed at fostering innovations in vascular treatment technologies. Included in the team are skilled researchers from Southeast University, South China University of Technology, and The University of Tokyo, indicating a robust partnership across borders.

What sets these stents apart from their predecessors lies in the unique material used for their fabrication. The team utilized a polycaprolactone-based shape-memory polymer composite that is particularly favorable in the context of medical implants. By employing advanced projection micro-stereolithography 4D printing technology, the researchers were able to create highly detailed micro-architected structures. This method not only ensures precision but also opens avenues for enhanced customization to cater to individual patient needs, a critical factor in medical device efficacy.

During the manufacturing process, the scientists were able to finely modulate the thermal transition temperature of the stents to around 37 degrees Celsius, using diethyl phthalate as a plasticizer. This significant manipulation enables the device to achieve a quick and reliable shape recovery without additional thermal equipment, making the implantation process more streamlined.

Rigorous testing was carried out to assess the mechanical properties and biological compatibility of the newly developed stents. Finite element simulations demonstrated optimal mechanical flexibility alongside adequate radial strength—characteristics essential for the stent to function effectively within the dynamic environment of human blood vessels. Tests utilizing human umbilical cells revealed excellent cytocompatibility, indicating that the new stents are well-tolerated by the body.

In vivo studies were conducted on murine models, further solidifying the potential for practical clinical applications. The outcomes suggest that these vascular stents are not only effective in laboratory settings but also show promising results in actual biological environments. Professor Umezu emphasizes the transformative potential of this new technology, noting that such developments could revolutionize the way cardiovascular treatments are approached, leading to more personalized and less invasive methodologies.

As the research team articulates, this development is not merely a technological achievement; it represents a paradigm shift in the clinical application of stents. The concept of adaptive vascular stenting with programmable mechanics allows for a new level of interaction between medical devices and the human body, paving the way for future innovations not just in vascular treatment but also in the broader field of implantable medical devices.

This important breakthrough could act as a catalyst in addressing existing challenges within the realm of vascular surgeries. With key advantages, including the potential to lower the required complications during procedures and enhance patient comfort, the new stents signal a forward-thinking approach to medical engineering. These devices might not only simplify the deployment process but also reduce the dependency on various surgical tools that can complicate these procedures.

Moreover, the implications of this research extend beyond cardiovascular treatments. The methodology developed could very well be adapted for other types of implantable devices that also need to interact seamlessly with the body’s natural environment, driving future research in the field of biofabrication and regenerative medicine.

This innovative work not only highlights the potential for increased operational feasibility but also emphasizes the engineering controllability necessary for the fabrication of patient-specific stents. As personalized medicine gains traction, the continuing refinement and adaptation of such medical technologies present profound opportunities to tackle an increasing array of health complications that affect millions globally. The researchers aim to make our healthcare approaches not just smarter, but more responsive to the diverse and evolving needs of patients, particularly those inhabiting the intricate landscape of vascular health.

The research findings offer hope not only for innovation in vascular stent technology but also embody a broader vision for the future of medical devices tailored to individual patients’ anatomical and physiological conditions. As the study results indicate, the landscape of cardiovascular treatment is on the brink of transformation, promising safer and more efficient care pathways for patients worldwide.

Subject of Research: Vascular Stents
Article Title: Adaptive 4D-Printed Vascular Stents with Low-Temperature-Activated and Intelligent Deployment
News Publication Date: January 15, 2026
Web References: Advanced Functional Materials DOI
References: None available
Image Credits: Credit Professor Shinjiro Umezu from Waseda University, Japan

Keywords

Cardiovascular disease, Bioengineering, Biomedical engineering, Regenerative medicine, Additive manufacturing, Polymers, Medical technology.

At the heart of this study lies a deceptively simple yet powerful mathematical model which captures the delicate balance between two fundamental forces: the repulsive interactions among particles and the spatial constraints imposed by their environment. By finely tuning these opposing influences, the researchers were able to predict with remarkable accuracy the equilibrium configurations that these particles adopt. This universality of patterns, emerging regardless of the particles’ material nature or scale, underscores a profound natural order that transcends individual physical properties.

The international collaboration, led by Dr. Paulo Douglas Lima of Brazil’s Federal University of Rio Grande do Norte and including Professor Simon Cox from Aberystwyth University’s Department of Mathematics, conducted a series of meticulous experiments utilizing diverse particle systems. Floating magnets, steel ball bearings, and delicate soap bubbles were each confined within specially designed containers to emulate different confinement conditions. Despite their intrinsic differences—in elasticity, mass, and interaction forces—all these particles conformed to the same geometric arrangements, validating the theoretical framework.

Such findings bear significant implications on a practical level, especially in the biomedical field. For instance, the ability to engineer particles that self-assemble predictably under confinement could revolutionize the development of drug delivery systems. Smart capsules that release therapeutics at controlled rates or in response to specific triggers rely heavily on the organization of particulate matter at microscopic scales. The universal principles detailed by this research offer a blueprint for tailoring these assemblies to achieve maximum efficacy and precision in treatment.

Beyond medical applications, the principles governing particle self-assembly provide fresh perspectives on the natural organization of biological tissues. Understanding how cells pack tightly while maintaining functionality is crucial to designing synthetic scaffolds that mimic natural tissue architecture. This research provides a mechanistic foundation that can guide bioengineers in crafting regenerative materials that promote optimal cellular organization and growth, potentially accelerating advances in regenerative medicine and organ repair.

The study’s underpinning mathematical model captures the competition between particle-particle repulsion and the degree of spatial confinement with elegant simplicity. This model posits that as particles repel each other, they attempt to maximize their mutual distances; simultaneously, the confining environment restricts their freedom to spread. The resultant compromise leads to highly ordered configurations, often forming clusters or shells of particles arranged in precise symmetrical patterns. Importantly, the model extends across scales and materials, marking a significant step toward a unified understanding of confined particle behavior.

Experimentally, the researchers’ approach was as innovative as their theoretical insight. Utilizing floating magnets involved creating repulsive dipole forces that kept each magnet apart within a two-dimensional plane, effectively simulating ideal conditions for observing self-assembly under repulsive confinement. In contrast, ball bearings provided a tangible example of granular materials, while soap bubbles illustrated soft, deformable particles governed by surface tension and minimal friction. These varied experiments reinforced the robustness of the theoretical predictions, demonstrating that the self-organizing phenomenon is not limited by particle rigidity or interaction type.

Professor Simon Cox remarked on the elegance of these findings, emphasizing how disparate systems converge to similar arrangements under confinement. He highlighted that the universality of these patterns serves as a compelling example of nature’s propensity towards order, even amidst apparent complexity and variability. This realization presents vast opportunities to harness these principles in engineered systems, potentially transforming manufacturing, materials science, and beyond.

Industrially, this newfound understanding extends to the optimal handling and transport of granular materials such as powders and pellets, which are notoriously difficult to pack and manage efficiently. The principles of self-assembly could inform container design and processing methods that minimize waste and damage while maximizing packing density and stability. This could lead to economic benefits across sectors ranging from pharmaceuticals to agriculture.

The collaboration’s findings have been detailed in the esteemed journal Physical Review E, reflecting thorough peer review and validation by the scientific community. This publication marks a significant contribution to interdisciplinary research, bridging mathematics, physics, engineering, and biomedical science. The team’s work not only advances fundamental knowledge but also underscores the importance of cross-border scientific partnerships in tackling complex challenges.

Looking ahead, the potential applications of this research are vast and multifaceted. One can envision engineered systems exploiting these self-assembling principles to create dynamic materials that adapt their structure in response to environmental changes or stimuli. Furthermore, exploring these phenomena in three-dimensional confinements and with active particles could unlock even deeper insights, laying the groundwork for future innovations in smart materials and synthetic biology.

Ultimately, this work reminds us that the natural world often follows elegant, universal principles that emerge across diverse systems. By deciphering these, scientists can transcend disciplinary boundaries and develop technologies that harmonize with nature’s inherent efficiencies. The ability to predict and control particle arrangements at multiple scales opens exciting pathways to innovative materials and medical breakthroughs that could redefine how we approach design and function in the physical world.

Subject of Research: Self-assembly and geometric pattern formation of repelling particles under spatial confinement.

Article Title: Self-assembled clusters of mutually repelling particles in confinement

News Publication Date: 29-Oct-2025

Web References: https://dx.doi.org/10.1103/1wcz-hhw6

Image Credits: Aberystwyth University

Keywords: Applied mathematics, Human health, Bioengineering, Magnets, Research universities, Universities

The core of this novel model resides in its ability to process continuous streams of physiological data gathered from wearable sensors, thereby allowing for early detection of subtle signs indicative of patient distress. Historically, clinical deterioration was identified through intermittent checks and manual observations, leading to potential delays in intervention. However, this new system is designed to operate round-the-clock, autonomously interpreting complex biometrics that might be overlooked or misinterpreted during routine medical evaluations.

Central to this advancement is the deployment of a sophisticated deep learning framework specifically tailored to parse high-dimensional time-series data. These algorithms excel in discerning patterns that escape traditional statistical methods, such as nuanced changes in heart rate variability, respiratory rhythms, and temperature fluctuations. The study meticulously validates the model using real-world patient data collected from diverse hospital wards, emphasizing robustness across different patient demographics and comorbidities.

The wearables themselves are lightweight, non-invasive devices that continuously monitor vital signs including electrocardiogram (ECG) readings, oxygen saturation levels, respiratory rate, and more. Equipped with secure wireless connectivity, these devices enable seamless data transmission to centralized hospital servers where the deep learning models analyze incoming streams in real-time. This infrastructure not only facilitates timely alerts but also ensures data integrity and patient privacy through encrypted channels conforming to stringent healthcare regulations.

One of the standout features of the model is its adaptability via continual learning, allowing it to refine its predictive accuracy as more data is accumulated from individual patients. This dynamic updating helps tailor risk assessments to personalized baseline patterns rather than relying solely on population averages, thereby reducing false positives and unnecessary interventions. Such personalized medicine approaches represent a significant paradigm shift, underscoring the potential of AI to transform clinical decision-making from reactive to proactive.

Clinical trials evaluating the model demonstrated significant improvements in early warning scores compared to conventional risk assessment tools. Importantly, the real-time continuous monitoring framework significantly shortened the response times for critical interventions, which correlates strongly with improved survival rates in acute deteriorations such as sepsis or cardiac events. Through retrospective analyses, the system also uncovered previously underappreciated precursors to patient decline, offering new avenues for medical research.

The integration of this wearable deep learning-based prediction system into existing hospital workflows is designed with end-user usability in mind. Physicians and nursing staff interact with intuitive dashboards displaying actionable insights rather than raw data, streamlining clinical decision-making without adding cognitive burden. Moreover, the system supports customizable alert thresholds to align with institution-specific protocols and patient risk profiles, enhancing both safety and operational efficiency.

Data security and ethical considerations have been a central focus throughout the device’s development lifecycle. The research outlines rigorous safeguards including de-identification processes, secure data storage mechanisms, and transparency protocols aimed at fostering trust among patients and healthcare professionals alike. The ethical use of AI in health monitoring, with respect to consent and data governance, is addressed comprehensively, setting a standard for future digital health innovations.

The study also highlights the scalable potential of the model beyond hospital settings, envisioning applications in remote patient monitoring scenarios and home healthcare. As healthcare systems grapple with rising costs and limited human resources, such AI-driven wearables could bridge critical gaps in patient surveillance, enabling early interventions that prevent hospital admissions or readmissions altogether. This aligns with broader healthcare transformation strategies emphasizing value-based care and patient empowerment.

From a technical standpoint, one of the key challenges that this research overcame involved the harmonization of heterogeneous sensor data to ensure consistency across diverse devices and environments. Advanced preprocessing pipelines were developed to mitigate noise, artifacts, and missing data, thereby ensuring the reliability of input signals. Additionally, the model employs explainable AI techniques to provide clinicians with interpretable rationale behind each prediction, fostering confidence and facilitating clinical validation.

The multidisciplinary collaboration uniting engineers, data scientists, clinicians, and ethicists was crucial to the success of this endeavor. Combining expertise from artificial intelligence and medical domains enabled the creation of a solution that not only harnesses technological sophistication but also resonates with practical clinical needs. Ongoing partnerships with healthcare institutions will further refine and scale the deployment based on real-world feedback and evolving standards.

Looking ahead, the researchers envision integrating this wearable predictive technology with broader hospital information systems including electronic health records (EHRs) and clinical decision support systems. Such integration could enable holistic patient management workflows combining physiological data with laboratory results, imaging, and existing risk assessments. The resultant ecosystem promises to be a powerful tool in both acute care and chronic disease management, substantially advancing personalized medicine.

The implications of this research extend into the burgeoning field of AI-driven healthcare, underscoring the transformative potential of continuous patient monitoring powered by machine learning. By enabling earlier and more precise identification of clinical deterioration, this approach offers a pathway to vastly improving patient safety, reducing healthcare costs, and optimizing resource allocation. As these technologies mature and become widely adopted, they hold the promise of reshaping hospital care paradigms on a global scale.

This development also serves as a shining example of how the convergence of wearable technology and artificial intelligence is ushering in a new era of medical innovation. Beyond prediction, ongoing work is focused on predictive prevention, exploring how interventions prompted by AI alerts can be personalized to maximize beneficial outcomes. The iterative feedback loop between data, prediction, and clinical action represented here is emblematic of the future of healthcare innovation.

In summary, this groundbreaking study presents a meticulously validated clinical wearable deep learning-based model for continuous in-hospital patient deterioration prediction. The research encapsulates a myriad of technological advancements, practical clinical integration strategies, and ethical considerations needed to translate AI innovations from experimental stages to clinical impact. As these wearable predictive systems gain traction, they are poised to become indispensable tools in saving lives and enhancing the quality of hospital care worldwide.

Subject of Research: Clinical wearable technology and deep learning for continuous in-hospital deterioration prediction.

Article Title: Development and validation of a clinical wearable deep learning based continuous inhospital deterioration prediction model.

Article References:
Scheid, M.R., Friedmann, B., Oppenheim, M. et al. Development and validation of a clinical wearable deep learning based continuous inhospital deterioration prediction model. Nat Commun 16, 9513 (2025). https://doi.org/10.1038/s41467-025-65219-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65219-8

The FMH principle posits a blurred boundary between food and medicine, emphasizing natural substances that confer health benefits beyond basic nutrition. Historically, such substances were employed in traditional Chinese medicine and various indigenous healing systems to address ailments resembling modern-day cancers. Today, the challenge lies in translating this rich heritage into rigorous scientific frameworks that validate efficacy, elucidate mechanisms, and ensure safety. The authors assert that FMH substances’ inherent pharmacological activity combined with their nutritional value and low toxicity makes them exemplary candidates for adjunctive cancer therapies, capable of complementing existing treatment modalities with minimal adverse effects.

From a biochemical perspective, FMH substances harbor a complex milieu of bioactive compounds, including polyphenols, flavonoids, alkaloids, and terpenoids, each potentially acting upon multiple molecular pathways implicated in carcinogenesis. Recent advances in analytical technologies, such as high-resolution mass spectrometry, have enabled unparalleled characterization of these compounds at the molecular level. Coupled with systems biology approaches like network pharmacology, researchers can now map intricate interactions between these multi-component mixtures and targeted cellular signaling networks, presenting a compelling case for their multi-targeted therapeutic potential in overcoming challenges like tumor heterogeneity and drug resistance.

The implications for cancer management are profound. Conventional therapies such as chemotherapy and radiotherapy, while often effective, are frequently limited by systemic toxicity, acquired resistance, and diminished patient quality of life. Integrating FMH-derived adjuncts into treatment regimens could enhance therapeutic efficacy by modulating tumor microenvironments, sensitizing cancer cells to cytotoxic agents, and ameliorating metabolic dysregulation frequently encountered in cancer patients. Moreover, the nutritional support provided by FMH substances may assist in correcting cancer-induced cachexia and improving overall patient resilience, thereby addressing both disease and host factors comprehensively.

Importantly, the research team stresses that their exploration is far from a nostalgic return to uncritical traditionalism. Rather, it represents a scientifically rigorous endeavor committed to disentangling empirical observations from anecdotal claims. Emerging tools such as organ-on-chip models and artificial intelligence-driven drug discovery platforms enable systematic evaluation of FMH therapies with unprecedented precision. These approaches permit not only dissection of pharmacodynamic properties but also simultaneous assessment of nutrient metabolism and toxicity, laying the foundation for refining dosing strategies and ensuring safety—even with chronic use.

Historical medical texts continue to inspire contemporary inquiry, with canonical works such as the Shang Han Za Bing Lun documenting ancient FMH formulations aimed at diseases resembling neoplastic conditions. Similarly, ethnopharmacological practices prevalent in regions like Sub-Saharan Africa and other developing areas underscore a globally recognized role for traditional medicine in holistic cancer care. Such rich cultural repositories offer a vast yet largely untapped source for novel compound discovery, especially when evaluated through the prism of modern scientific validation. This global perspective encourages a synthesis of diverse medicinal heritages into a unified, evidence-based framework for integrative oncology.

The multifaceted nature of FMH also aligns perfectly with the contemporary shift from a purely “disease-centered” model of cancer care to a broader “health-centered” paradigm. Beyond eradicating malignant cells, this approach advocates for restoration of systemic balance and enhancement of patient well-being. FMH therapies fit within this philosophy by simultaneously targeting multiple etiological and symptomatic facets of cancer progression. Furthermore, their cost-effectiveness and adaptability across the cancer care continuum—from prevention through recovery—position them as promising tools to enhance accessibility in resource-limited settings, where conventional treatments may be scarce or unaffordable.

Clinical translation nevertheless remains a formidable but surmountable hurdle. The authors advocate for a phased research process beginning with in-depth fundamental studies to parse out active constituents and their synergistic or antagonistic interactions. This should be followed by preclinical validation using innovative models that recapitulate human tumor biology and metabolic complexities. Subsequently, carefully designed clinical trials are imperative to confirm safety, optimal dosing, and efficacy. Such rigorous methodologies will help move FMH interventions from purported remedies to standardized, clinically actionable therapies, supported by regulatory approval and integrated guidelines.

Furthermore, attention must be given to exploring the differential effects of whole FMH formulations versus isolated active ingredients. Whole extracts may exploit synergistic interactions among constituent compounds, producing augmented anti-cancer effects. Conversely, isolating specific molecules permits dose precision and mechanistic clarity, both critical for meeting clinical trial and regulatory standards. Bridging this knowledge gap will require coordinated efforts among pharmacologists, oncologists, chemists, and nutrition scientists.

The societal and cultural dimensions of adopting FMH-based therapies should not be underestimated. High patient acceptance and cultural resonance can drive adherence, enhancing therapeutic outcomes. Meanwhile, their use as adjuncts reduces the burden of side effects common to conventional therapies, potentially improving patients’ quality of life and treatment sustainability. However, cultivating this acceptance demands transparent communication and education grounded in robust scientific evidence, thereby dispelling misconceptions and avoiding exploitation through unregulated claims.

Ultimately, the integration of FMH into modern oncology represents a bold endeavor to harness the best of ancient insights and modern science. Co-corresponding author Professor Gokhan Zengin emphasizes the necessity for unwavering scientific rigor supported by persistent research investment and favorable policy frameworks. With such infrastructure in place, the development of standardized extracts, prioritization of clinical trials involving combination therapy and nutritional support, and establishment of comprehensive clinical guidelines for FMH use could redefine adjunctive cancer care.

In conclusion, while FMH is not a panacea, its thoughtful and evidence-based incorporation into contemporary oncology promises to enhance patient outcomes, alleviate therapeutic toxicity, and democratize access to cancer care worldwide. This emerging interdisciplinary field epitomizes the future of integrative medicine—where tradition and innovation collide to produce clinically meaningful advances.

Subject of Research: Food and medicine homology (FMH) substances as potential adjunctive therapies in cancer treatment.

Article Title: Food and medicine homology in cancer treatment: traditional thoughts collide with scientific evidence

News Publication Date: 20-Jun-2025

Web References: DOI: 10.26599/FMH.2025.9420120

Keywords: Food and medicine homology, FMH, cancer therapy, natural compounds, adjunctive treatment, systems medicine, pharmacology, tumor heterogeneity, drug resistance, nutrition support, integrative oncology, traditional medicine, multi-target therapy

This research addresses a critical need in both medical science and robotics. Beyond the biological implications, understanding the dynamics of defecation can lead to better treatment offerings for patients suffering from gastrointestinal disorders. These disorders can be debilitating, significantly impacting individuals’ quality of life. Therefore, simulating these processes with precision can enhance medical training and device development.

The unique soft actuators developed in this study are notable for their flexibility and ability to adapt to various stresses. Unlike traditional rigid robotics, these soft actuators can mimic the subtle and intricate muscle movements of the human rectum. This mimicry is essential for simulating real-world conditions during medical assessments and treatments. The ability of these soft actuators to bio-adapt offers a sustainable approach to creating medical devices that require less invasive procedures.

One of the standout features of the actuators is their bio-inspired design. By modeling these devices on the natural function of the rectum, the researchers can create highly accurate simulations. Humans possess a complex layer of sphincter muscles that manage bowel control, and replicating this functionality may offer new insights into mechanistic pathways that govern this biological process. This not only aids medical understanding but also enhances the logistics of developing effective treatment modalities.

Furthermore, the researchers employed advanced materials science techniques to cultivate soft actuators responsive to varying pressure levels. The soft actuators’ response to pressure reflects the human body’s natural tendency to react in similar circumstances, thereby enhancing the realism of simulations. This adaptability could lead to significant breakthroughs in how gastrointestinal issues are understood and treated.

In addition to their practical applications in medical fields, these soft actuators could revolutionize robotics, particularly in creating more human-like machines capable of sensitive tasks. The incorporation of bio-inspired mechanics opens a myriad of opportunities for developers, providing robots with the potential to operate safely around humans. Areas like elder care, rehabilitation, and assistive technologies could benefit greatly from these advancements, providing comfort and improving users’ experiences.

The scientists emphasized the importance of collaboration between fields. The convergence of biology, engineering, and design principles has equipped the research team to tackle longstanding challenges in understanding bodily functions. This interdisciplinary nexus is crucial as it could set a precedent for future innovations, not only in gastrointestinal applications but throughout the landscape of soft robotics.

The findings from this study could invite a ripple effect across various sectors. Medical institutions may adopt these actuators for educational purposes, allowing students and practitioners to observe and understand the nuances of human anatomy effectively. Educators could utilize these devices to simulate real-life scenarios, which can improve diagnostic skills and procedural techniques without putting patients at risk.

Meanwhile, the implications of this technology extend to the manufacturing sector, where industries are striving to integrate more adaptive and intelligent systems. The actuators’ ability to react and adjust to environmental stimuli transfers seamlessly into manufacturing processes requiring automation, customization, and efficiency. Companies looking to enhance their robotics capabilities will benefit from insights gleaned from this innovative research.

Moreover, the implications for healthcare innovation cannot be understated. This technology may enhance treatments for patients suffering from chronic disorders or rehabilitative situations arising from surgery or other health interventions. By providing realistic simulations, practitioners could prepare and tailor their approaches based on individual needs. This personalized medicine model could advance significantly as a result of these developments.

As investigations continue, it is clear that the bio-inspired circular soft actuators represent not only a leap forward in understanding human physiological processes but also a shining example of how science can transcend traditional boundaries. This work exemplifies the potential for technology to mirror biological systems, paving the way for advancements that improve medical care, robotic assistance, and beyond.

As awareness of these innovations grows, discussions around the challenges of development, ethics in robotic design, and patient care will undoubtedly arise. Encouraging a dialogue surrounding the implications of such technology can ensure that the evolution of medical and robotic practices aligns with ethical standards and prioritizes patient welfare.

The journey of this scientific endeavor is just beginning, with future research promising further exploration into refining these actuators. This development marks a notable chapter within the ever-advancing narrative of how technology empowers healthcare and robotics. Clearly, the bridge between bio-engineering and robotics is expanding, and the scientific community eagerly anticipates the next set of discoveries to emerge from this synthesis.

Subject of Research: Bio-inspired circular soft actuators for simulating defecation process of human rectum.

Article Title: Bio-inspired circular soft actuators for simulating defecation process of human rectum.

Article References:

Mao, Z., Suzuki, S., Wiranata, A. et al. Bio-inspired circular soft actuators for simulating defecation process of human rectum.
J Artif Organs 28, 252–261 (2025). https://doi.org/10.1007/s10047-024-01477-5

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10047-024-01477-5

Keywords: Bio-inspired actuators, soft robotics, human defecation simulation, gastrointestinal disorders, interdisciplinary research, medical applications, robotic technologies.

Journals under the JMIR Publications umbrella have consistently embodied the convergence of technology and health sciences, and their latest rankings further validate this trajectory. Twelve of these journals achieved first quartile (Q1) status across their respective disciplines, signifying their position among the top 25% of peer publications globally. Particularly noteworthy is the designation of six journals within the top 10% of their specific subject categories, signaling not only high citation rates but also robust scholarly influence and thematic relevance.

The range of fields these journals cover is both diverse and specialized, reflecting the multifaceted nature of contemporary medical and health informatics research. Prestigious titles such as the Journal of Medical Internet Research, which ranks 12th out of 153 in Health Informatics with a Q1 rating at the 92nd percentile, and JMIR Medical Education, achieving an exceptional Q1 97% ranking in Education, highlight the vital intersections of digital communication, pedagogy, and health innovation. These metrics reinforce the foundational role that JMIR’s journals play in advancing knowledge across multidisciplinary domains including rehabilitation, psychiatry and mental health, public health surveillance, and pediatrics.

The attainment of first-time CiteScore rankings by three journals—JMIR AI, JMIR Biomedical Engineering, and the Online Journal of Public Health Informatics—marks a significant developmental stage for these publications and their editorial teams. Notably, JMIR AI entered the marketplace with a robust Q2 standing, evidencing the rapid recognition of emerging subfields such as artificial intelligence within medical research. This achievement highlights the evolving landscape of health technology and the vital need for dedicated platforms that foster discourse on cutting-edge methodologies and applications.

Moreover, 16 journals under JMIR Publications showcased year-over-year growth in their CiteScore values, demonstrating sustained advancements in both researchers’ engagement and the journals’ scholarly reach. For example, JMIR Perioperative Medicine improved to a Q2 standing at the 73rd percentile within the Health Professions category, indicating a strengthening citation footprint in clinical and procedural research contexts. Similarly, the Asian Pacific Island Nursing Journal and JMIR Diabetes have also manifested notable increases, bolstering their roles as pivotal resources for specialized healthcare communities.

The integrity of these rankings is anchored in the rigorous peer-review processes and technological innovations that JMIR Publications integrates within its editorial framework. By leveraging open science principles and promoting transparency in data sharing and research methodologies, JMIR supports an academic ecosystem where the reproducibility and reliability of findings are paramount. This philosophy ensures that high citation counts correspond not merely to popularity but also to substantive contributions advancing digital health sciences.

JMIR’s editorial leadership emphasizes the collective effort of researchers, reviewers, authors, and editorial staff who drive these successes. Scientific Editorial Director Tiffany I Leung, MPH, MD, FAMIA, articulates that the journal portfolio’s expansion and prominence reflect a vibrant research community committed to rigorous investigation and innovation. This community-centric approach aligns with broader movements to democratize scientific knowledge, championing open access models that enhance the availability and dissemination of health-related research outputs.

Despite the positive spotlight on CiteScore, JMIR Publications advocates for a critical and informed use of citation-based metrics. The organization advises that while CiteScore provides valuable insights into journal performance, alternative impact metrics and qualitative assessments should complement these scores to create a holistic understanding of scholarly influence. This stance is particularly relevant in the era of interdisciplinarity where citation practices vary markedly among fields, and where groundbreaking articles in emerging areas might initially accrue lower citation volumes despite substantial societal impact.

The current achievements of JMIR Publications underscore a pivotal moment in digital health publishing. The portfolio’s robust representation across multiple disciplines—from clinical informatics to health policy and rehabilitation sciences—illustrates the publisher’s strategic positioning at the forefront of scientific communication. By continuously refining editorial standards, fostering author advocacy, and harnessing innovative dissemination tools, JMIR Publications is setting new benchmarks for open access publishing in the biomedical and health sectors.

Central to this narrative is the recognition that impactful research transcends citation numbers alone. JMIR’s commitment to scientific rigor, accessibility, and advancement of open science principles facilitates a research environment poised for both academic excellence and real-world application. This ethos resonates through the improved CiteScore metrics, spotlighting the tangible contributions of JMIR journals to digital health innovation, clinical practice, and public health policy development.

JMIR’s ongoing success story is a testament to how modern scholarly publishers can navigate the complexities of evolving research landscapes while championing transparency and inclusivity. Their CiteScore milestones affirm that with a well-managed blend of editorial expertise and technological acumen, it is possible to elevate the scientific dialogue and foster impactful knowledge exchange globally. As digital health continues to advance at unprecedented speeds, JMIR Publications remains an essential platform for researchers and clinicians seeking to shape the future of medicine through data-driven insights and open scholarship.

Looking forward, JMIR Publications’ trajectory signals promising developments in fields such as artificial intelligence integration, rehabilitation technology, mental health informatics, and educational innovation. The journal set’s strong performance on CiteScore suggests that forthcoming publications will continue to influence evolving healthcare paradigms and technology applications. Scholars, practitioners, and policymakers alike will increasingly depend on JMIR’s journals as authoritative voices guiding best practices, research trends, and policy formulation in digital health arenas.

In summary, JMIR Publications’ 2024 CiteScore achievements represent not only quantitative metrics of academic impact but also qualitative reinforcement of its leadership role in digital health publishing. This extensive recognition fosters broad confidence in the publisher’s portfolio, stimulates further research collaborations, and inspires continued investment in pioneering studies that harness the potential of technology to transform health outcomes worldwide.

Subject of Research: Digital Health Publishing and Journal Impact Metrics

News Publication Date: June 10, 2025

Web References:

• https://jmirpublications.com/
• https://jmirpublications.com/announcements/572

Image Credits: JMIR Publications

Keywords: Medical journals, Science journalism, Open access, Health care, Health equity, Health care policy, Health care delivery, Nursing, Patient monitoring, Hospitals, Rehabilitation centers

Thyroid cancer, a prominent malignancy globally and within Hong Kong, is traditionally managed through a dual-system approach that relies heavily on manual integration of clinical information. The widely accepted American Joint Committee on Cancer (AJCC) Tumour-Node-Metastasis (TNM) system stratifies cancer by its pathological stage, while the American Thyroid Association (ATA) provides a risk classification framework crucial for prognostic evaluations and treatment planning. Despite their importance, these systems demand meticulous review and interpretation of multifaceted medical records, often resulting in a time-intensive process for healthcare professionals and leaving room for human error.

The innovation presented by the HKUMed-led team harnesses the power of large language models (LLMs), sophisticated AI frameworks capable of interpreting human language with remarkable nuance and contextual understanding. By adapting models such as ChatGPT and the newly introduced DeepSeek, the research team developed an AI assistant designed to parse complex clinical documents including pathology reports, operation records, and clinical notes. This AI leverages deep learning techniques to extract critical entities and information, bridging the gap between unstructured textual data and actionable clinical insights.

Central to the model’s development was the integration of four open-source LLMs—Mistral AI’s Mistral, Meta’s Llama, Google’s Gemma, and Alibaba’s Qwen. Unlike proprietary online models, these offline LLMs allow for local deployment, an essential factor in maintaining patient data privacy and complying with stringent health data regulations. Training occurred using pathology reports from 50 thyroid cancer patients sourced from The Cancer Genome Atlas Programme (TCGA), a well-regarded open-access database, followed by rigorous validation against an extended cohort of 289 TCGA cases alongside 35 meticulously crafted pseudo cases generated by experienced endocrine surgeons, ensuring robustness and clinical relevance.

Remarkably, the AI assistant’s fusion of outputs from all four language models elevated its performance to notable levels, achieving accuracy rates between 88.5% to 100% in ATA risk classification and between 92.9% to 98.1% for AJCC cancer staging. These figures compare favorably to manual chart reviews and highlight the system’s potential as a transformative clinical tool. Beyond accuracy, one of the most impactful outcomes of this technology is its capability to reduce clinicians’ preparatory workload by almost half, streamlining clinical workflows and enabling more focused patient interactions.

Professor Joseph T Wu, Sir Robert Kotewall Professor in Public Health and Managing Director of InnoHK D24H, emphasized the AI model’s dual advantage: high precision combined with offline operation. By enabling local analysis of sensitive clinical data, the AI solution prioritizes patient confidentiality without sacrificing technological sophistication—a critical balance in today’s healthcare landscape. This offline capability ensures that hospitals and clinics can adopt the system without concern for data breaches or regulatory hurdles associated with cloud-based solutions.

Further comparative analyses highlight the AI assistant’s competitive edge. Tests employing a “zero-shot approach” compared the model against recent versions of DeepSeek (R1 and V3) and GPT-4o, both leading online language models renowned for their vast training datasets and computational power. Impressively, the HKUMed AI model matched these high-caliber systems in performance, an achievement that underscores its engineering excellence and adaptability within resource-constrained environments.

Dr Matrix Fung Man-him, Clinical Assistant Professor and Chief of Endocrine Surgery at HKUMed, underscored the tangible clinical benefits rendered by the AI platform. The model not only excels in parsing intricately detailed pathological and surgical documentation but also condenses the interpretive burden on surgeons and endocrinologists. By delivering concurrent results for cancer stage and risk stratification based on internationally recognized frameworks, it provides a comprehensive clinical picture faster and with greater accuracy.

The versatility of the AI system hints at its broad applicability. Both public institutions and private healthcare providers, locally and internationally, stand to benefit from deploying this technology, which seamlessly integrates into existing clinical infrastructures. Dr Fung expressed optimism that the model’s real-world implementation will translate directly into enhanced efficiency for clinicians, improved quality of care for patients, and increased opportunities for physicians to focus on patient counseling and treatment planning rather than administrative burden.

Aligned with the Hong Kong Government’s commitment to leveraging AI in healthcare, as exemplified by recent developments like the LLM-based medical report writing system introduced by the Hospital Authority, the research team is preparing for subsequent phases. These involve large-scale validation using expansive, real-world patient data sets to ensure robustness and generalizability. Upon successful testing, rapid deployment into hospital systems and clinical workflows is anticipated, heralding a new era of AI-assisted medicine that could redefine operational and therapeutic efficiency.

The research team responsible for this breakthrough reflects a confluence of expertise spanning public health, clinical medicine, and family medicine research. Led by Professor Joseph Wu Tsz-kei, Dr Matrix Fung Man-him, and Dr Carlos Wong King-ho, the collaboration also includes first authors Dr Eric Tang Ho-man and Dr Tingting Wu. Such multi-disciplinary cooperation, under the auspices of HKUMed and supported by initiatives like the Hong Kong Jockey Club Global Health Institute and the Innovation and Technology Commission’s InnoHK program, exemplifies the integrative approach necessary for modern medical innovation.

The InnoHK Laboratory of Data Discovery for Health (InnoHK D²4H), spearheading the project, embodies a bold vision for precision medicine. They aspire to harness unparalleled data resources and apply frontier analytics to safeguard global health while advancing individualized medical care. By fostering collaborations across scientific disciplines and sectors, InnoHK D²4H positions itself at the forefront of transforming healthcare technology in Hong Kong and beyond, striving toward ambitious goals with wide-reaching implications for worldwide disease management.

With an article slated for publication in the prestigious journal npj Digital Medicine, this research heralds a promising intersection of artificial intelligence and cancer diagnostics. As thyroid cancer remains a critical public health challenge, innovations like this AI model offer a beacon of hope for more efficient, accurate, and privacy-conscious clinical practices that could set new standards for patient care around the world.

Subject of Research: Not applicable

Article Title: Developing a named entity framework for thyroid cancer staging and risk level classification using large language models

News Publication Date: 1-Mar-2025

Web References:
https://www.nature.com/articles/s41746-025-01528-y
http://dx.doi.org/10.1038/s41746-025-01528-y

References:
Wu, J. T., Fung, M. M-h., Wong, C. K-h., Tang, E. H-m., Wu, T., et al. Developing a named entity framework for thyroid cancer staging and risk level classification using large language models. npj Digital Medicine (2025). DOI: 10.1038/s41746-025-01528-y.

Image Credits: The University of Hong Kong

Keywords:
Thyroid cancer, Public health, Clinical research

Rheumatoid arthritis is a chronic condition where the immune system betrays the body by attacking its healthy tissues. This dysregulation can lead to significant inflammation, primarily affecting the joints, but it can also extend its grasp to vital organs such as the heart and lungs. Currently, it is estimated that 18 million people suffer from RA worldwide, with approximately 1.5 million residing in the United States. Notably, the disease disproportionately affects women, with nearly three times as many cases reported in females compared to males.

The current therapeutic options available for RA primarily target the inflammatory processes that occur after the disease has manifested. These treatments can provide significant relief but fail to address the critical challenge of prevention. Understanding the biological mechanisms behind RA is complex, as its exact cause remains elusive. Genetic predispositions combined with various environmental factors contribute to the onset of the disease, but a comprehensive understanding is still developing.

Emerging studies suggest that individuals who will eventually exhibit RA symptoms may exhibit abnormal immune responses even years prior to the diagnosis. These preclinical phases present a window of opportunity for early intervention strategies; however, the variability in this phase complicates predicting disease onset. Some individuals with detectable immunological abnormalities may never progress to RA, while others may do so rapidly. Consequently, the quest for accurate predictive markers becomes essential for developing preventive measures.

Dr. Zhang’s research situates itself at this critical juncture, where data science and translational medicine converge. With a unique access to large-scale datasets comprising genetic, genomic, and epigenetic information obtained on single-cell levels, her work strives to refine the predictive models for identifying individuals at risk for RA. Applying advanced machine learning algorithms enables her team to analyze diverse data sources and extract significant patterns that could foreshadow disease progression.

In her recent publication, "Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis," Zhang and her team undertook an extensive analysis of immune cell populations among individuals identified as at-risk versus those already exhibiting symptoms, alongside a healthy control group. Through a rigorous examination of RNA and protein expressions, they revealed substantial differences in immune cell types, particularly highlighting specific T cell subpopulations that were significantly expanded among the at-risk cohort.

The findings from Zhang’s research could potentially reshape the current understanding of RA onset, providing promising leads for early intervention. Identifying these markers is pivotal; it not only offers insight into who may be more likely to develop RA but could also inform the creation of tailored preventive strategies. However, Zhang emphasizes that while the initial findings are substantial, validating these markers requires further extensive study across broader and more diverse populations to confirm their reliability.

As part of her ongoing research, Dr. Zhang secured a competitive $150,000 grant from the Arthritis Foundation, aimed at advancing her project supported by the findings from her recent publication. Her team intends to delve deeper into complex datasets gathered from a prominent preclinical trial, StopRA, which might elucidate the immune changes that precede RA symptoms. This collaborative effort alongside renowned rheumatologist Dr. Kevin Deane is designed to provide deeper insights into the disease’s progression.

Dr. Zhang’s approach is not only a marriage of technology and medicine but also builds upon the rich tapestry of research and clinical expertise found at the University of Colorado Anschutz Medical Campus. The availability of multidisciplinary collaboration enhances the depth of her investigations, providing a fertile ground from which innovative methodologies can flourish and translate into meaningful clinical applications.

As she continues to bridge this critical gap between computational advances and clinical realities, Zhang exemplifies the transformative potential of AI in healthcare. Her vision is to foster a future where predictive diagnostics for RA and other autoimmune diseases are not merely aspirational but fully integrated into clinical practice, enabling earlier intervention and ultimately improving patient outcomes.

The nexus of Dr. Zhang’s work sheds light on the importance of comprehensively understanding the immunological landscape preceding disease presentation. By leveraging sophisticated data analytics, her research is paving the way for significant strides toward unraveling the complexities of rheumatoid arthritis. The identification of specific immune markers could eventually lead to the development of preventive measures that would forever change how we approach this debilitating disease.

With autoimmune diseases like RA representing a substantial challenge to global health, the urgency for innovative research approaches cannot be overstated. Dr. Zhang’s contributions are not only groundbreaking but also essential in charting the course for future research and clinical practices. As the scientific community moves forward, her dedication to harnessing artificial intelligence and data-driven methodologies promises to redefine our fight against rheumatoid arthritis, providing hope for millions at risk.

Through such increasingly interconnected research efforts, we may soon witness a transformative shift toward proactive healthcare, where prevention takes precedence over reactive treatment. The future of rheumatoid arthritis management is on the horizon, shaped by the relentless curiosity and innovative spirit of researchers like Dr. Fan Zhang.

Subject of Research: Rheumatoid Arthritis
Article Title: Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
News Publication Date: 17-Mar-2025
Web References: Journal of Clinical Investigation DOI
References: None available
Image Credits: None available

Keywords: Rheumatoid Arthritis, Artificial Intelligence, Predictive Modeling, Autoimmune Disease, Immune System, Early Intervention, Machine Learning, Translational Medicine.

Translational research stands at the intersection of laboratory and clinical practices, serving as a vital conduit for translating fundamental scientific findings into novel therapeutic interventions. It is an arena that demands the integration of diverse disciplines and a profound understanding of both basic science and clinical applications. As such, the award seeks candidates who have not only achieved success within their field but who have also demonstrated a significant impact on patient care and treatment paradigms.

The recipient of the 2026 Watanabe Prize will be awarded a substantial $100,000 and will have the opportunity to visit Indianapolis from September 16-18, 2026. This visit is designed to facilitate knowledge sharing and engagement with audiences at the Indiana University School of Medicine and its affiliated institutions. As part of the experience, the awardee will also deliver a keynote address at the Indiana Clinical and Translational Sciences Institute Annual Meeting, further underscoring the recognition of their contributions to the field.

The nomination process is designed to be transparent and thorough. Candidates need to submit a comprehensive application that includes their current curriculum vitae, laying out their academic and research credentials clearly. Additionally, nominators are required to provide a detailed letter highlighting the nominee’s major accomplishments in translational research. This letter should not only outline the individual’s achievements but also articulate the broader implications of their work on science and medicine, evidencing how their contributions have fostered advancements in therapeutic interventions and patient outcomes.

Candidates should remember that the availability for travel to Indianapolis during the specified dates is a prerequisite for nomination. This stipulation ensures that the prize winner can engage actively with the academic and clinical communities in Indiana, fostering dialogue and potentially inspiring future collaborations.

The Watanabe Prize is named in honor of the late August M. Watanabe, a distinguished figure whose influence in translational research has left an indelible mark on the health landscape both nationally and internationally. Watanabe’s career began at Indiana University in 1972, where he held significant roles including chair of the Department of Medicine from 1983 until 1990. His subsequent tenure at Eli Lilly and Company culminated in him becoming the executive vice president, where he was pivotal in the development and launch of eleven new drugs. His contributions not only advanced the pharmaceutical industry but also significantly improved patient care across the globe.

This prestigious prize has recognized many eminent researchers in its history, fostering a culture of excellence in scientific inquiry and diligence in clinical application. Among the past awardees are luminaries such as Kevan Herold, Craig B. Thompson, and Huda Zoghbi, all of whom have made pioneering contributions in their respective fields. By placing the focus on translational research, the Watanabe Prize not only honors individual achievements but also promotes the vital importance of bridging research and clinical practice to improve the health outcomes for patients.

As the nomination deadline approaches, there is an increasing anticipation in the research community regarding who will emerge as the next leading figure in translational research. The selection of the 2026 prize winner will not only spotlight the individual’s prior achievements but also inspire a new generation of scientists and clinicians committed to advancing therapeutic practices.

The spirit of the Watanabe Prize transcends merely recognizing scientific brilliance; it embodies a movement toward collaborative and interdisciplinary methodologies in research that prioritize human health outcomes. When researchers are encouraged to focus their efforts on translating discoveries into real-world therapies, it paves the way for a future where innovative solutions to pressing health issues are more readily available.

In conclusion, the August M. Watanabe Prize stands as a beacon of distinction in the field of translational research. As nominations for the 2026 prize open up until May 15, 2025, it presents an opportunity for the scientific community to recognize the critical work being done across the globe in the realm of medicine and health. Those who are eligible are encouraged not only to submit nominations but to reflect on the transformative power of their research in the lives of patients and the health systems worldwide.

Subject of Research: Translational Research
Article Title: Indiana University School of Medicine Opens Nominations for the 2026 August M. Watanabe Prize in Translational Research
News Publication Date: [Publication Date Here]
Web References: [References Here]
References: [References Here]
Image Credits: [Credits Here]

Keywords: Translational research, Indiana University, Watanabe Prize, medical research, healthcare innovation.